The business world is always looking for new ways to address the ever-growing obesity epidemic in America. Here's a rundown of the next round of potential slimming strategies, and the companies whose success could fatten up investors' returns.
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.
An expert panel will review Vivus' potential blockbuster drug Qnexa on Thursday, with the FDA making a decision in October. The FDA acknowledges the drug's effectiveness in cutting weight, but it will certainly draw scrutiny over its side effects.